<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24798599</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>03</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1857-9345</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>35</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2014</Year>
            </PubDate>
          </JournalIssue>
          <Title>Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)</Title>
          <ISOAbbreviation>Pril (Makedon Akad Nauk Umet Odd Med Nauki)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Wilson's disease.</ArticleTitle>
        <Pagination>
          <StartPage>93</StartPage>
          <EndPage>98</EndPage>
          <MedlinePgn>93-8</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Wilson's disease (WD) is a disorder of copper transport resulting from the defective function of a copper transporting P-type ATPase, ATP7B. The WD incidence is approximately 1/50-10,000 live births worldwide. Clinical manifestations of WD may be of any kind, but usually the symptoms of presentation are hepatic or neuropsychiatric, with a vast range of disturbances for both groups of symptoms. In children, however, clinical symptoms may be absent, making the diagnosis of the disease more difficult than in adults. Hepatic manifestations may range from asymptomatic minor biochemical disturbances, to acute, but mostly chronic, hepatitis, cirrhosis or severe fulminant hepatic failure. The spectrum of neurological manifestations is wide, including tremor, hypersalivation, Dysarthria, coordination defects, dystonia, ataxia. The spectrum of psychiatric manifestations is considerable and may include different disturbances such as altered working performance, anxiety, depression and antisocial behaviour. Kayser-Fleischer rings (KF) are present in 95% of patients with neurological symptoms and somewhat over half of those without neurological symptoms. In children presenting with liver disease, KF rings are usually absent. To obtain a more reliable diagnosis of WD, the Leipzig scoring system was proposed by an international consensus of experts. Wilson's disease copper overload is treated with chelating agents such as penicillamine, trientine and tetrathiomolybdate. Zinc is used mostly for mantainance therapy or the treatment of asymptomatic WD patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Loudianos</LastName>
            <ForeName>Georgios</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Ospedale Regionale Microcitemie, ASL 8, Cagliari, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lepori</LastName>
            <ForeName>Maria Barbara</ForeName>
            <Initials>MB</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Sanità publica, medicina clinica e molecolare, Università di Cagliari, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mameli</LastName>
            <ForeName>Eva</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Sanità publica, medicina clinica e molecolare, Università di Cagliari, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dessì</LastName>
            <ForeName>Valentina</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Sanità publica, medicina clinica e molecolare, Università di Cagliari, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zappu</LastName>
            <ForeName>Antonietta</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Sanità publica, medicina clinica e molecolare, Università di Cagliari, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>North Macedonia</Country>
        <MedlineTA>Pril (Makedon Akad Nauk Umet Odd Med Nauki)</MedlineTA>
        <NlmUniqueID>101677081</NlmUniqueID>
        <ISSNLinking>1857-9345</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019468" MajorTopicYN="Y">Disease Management</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006527" MajorTopicYN="Y">Hepatolenticular Degeneration</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2014</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24798599</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
